Prof. Ray explains how he decides on the amount of LDL-c lowering that is needed in a given patient, and why he chooses this approach.

The ICONIC study provides support for the hypothesis that higher-density calcified plaques are more stable, as patients who had ACS had lower high-density plaque volume than those without an event.

The new ESC/EAS Dyslipidaemia Guidelines focus on high-risk patients, and prof. Laufs shares evidence for the treatment recommendations. Test your knowledge

Prof. Landmesser shows data that form the rationale behind new guideline recommendations, among which the lower LDL-c target for patients at very high risk.

Prof. Lüscher paints a picture of how atherosclerosis has been a fact of human life throughout time, and the evolution of insights on how to lower LDL-c and its associated CV risk.

Presence of calcified plaques have been found in the mummified remains of three of four studied young Inuit individuals who lived 500 years ago.

AHA 2019 The 9-months data of the EVAPORATE study show slowing of several markers of plaque progression, although the primary endpoint of low attenuation plaque was not met.

Exploratory analysis identifies predictors of plaque erosion in patients with ACS who underwent OCT imaging. A combination of non-traditional risk factors can increase the probability of erosion to up to 73%.

Final results from the open-label OSLER-1 study on evolocumab show long-term reduction in LDL-C levels without attenuation of the LDL-lowering effect and consistent safety and tolerability profiles during 5-years.

Prof. Jukema explains the mechanism of epigenetics and how the BET inhibitor apabetalone can potentially impact CVD. In addition, he presents findings of first clinical studies with apabetalone.

Phase 3 ORION-11 results up to 18 months show efficacy of inclisiran, which prevents production of the PCSK9 protein, consistent with earlier studies and an at least as favorable safety profile.

In subjects without established CVD, assessment of CAC contributes to identify high-risk subjects who will benefit from low dose rivaroxaban.